Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium

Blood (2021) 138 (Supplement 1): 3396.

https://doi.org/10.1182/blood-2021-151313

Published: 2021

Journal Articles

PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

Kristie A. Blum, Jeffrey G. Supko, Michael Maris, Ian W. Flinn, Andre H. Goy, Anas Younes, Suresh Bobba, Adrian Senderowicz, Sergey Efuni, Ronda Rippley, Jeremy S. Abramson

Blood (2021) 138 (Supplement 1): 1202.

https://doi.org/10.1182/blood-2021-150852

Published: 2021

Journal Articles

A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia

Jennifer R. Brown, MD PhD, Sarah R. Walker, PhD, Lisa N. Heppler, Svitlana Tyekucheva, Erik Nelson, PhD, Josephine L. Klitgaard, MSc, PhD, Maria Nicolais, MD, Yasmin Kroll, Michael Xiang, MD PhD, Jennifer E. Yeh, MD PhD, Mousumi Chaudhury, Zachary T. Giaccone, Stacey Fernandes, Jeffrey G. Supko, PhD, Catherine J. Wu, MD, David A. Frank, MD PhD

Blood (2018) 132 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2018-99-118921

Published: 2018

Journal Articles

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Blood (2016) 128 (22): 175.

https://doi.org/10.1182/blood.V128.22.175.175

Published: 2016

Journal Articles

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Dan T. Vogl, Noopur Raje, MD, Parameswaran Hari, MBBS, MD MRCP, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, PhD MD, Paul G. Richardson, Sagar Lonial, MD, David Tamang, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 4764.

https://doi.org/10.1182/blood.V124.21.4764.4764

Published: 2014

Journal Articles

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma

Andrew J Yee, MD, Peter M. Voorhees, MD, William Bensinger, Jesus G. Berdeja, MD, Jeffrey G Supko, PhD, Paul G. Richardson, David Tamang, PhD, Simon S Jones, PhD, Gretchen Patrick, Catherine Wheeler, MD, Noopur Raje, MD

Blood (2014) 124 (21): 4772.

https://doi.org/10.1182/blood.V124.21.4772.4772

Published: 2014

Journal Articles

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial

Andrew Yee, Peter Vorhees, MD, William I. Bensinger, MD, Jesus Berdeja, MD, Jeffrey G Supko, PhD, Paul G. Richardson, MD, Simon S Jones, PhD, Gretchen Patrick, Catherine Wheeler, MD, Noopur Raje, MD

Blood (2013) 122 (21): 3190.

https://doi.org/10.1182/blood.V122.21.3190.3190

Published: 2013

Journal Articles

Results Of The DFCI ALL Consortium Protocol 05-001 For Children and Adolescents With Newly Diagnosed ALL

Lewis B. Silverman, MD, Kristen E. Stevenson, MS, Uma H. Athale, M.D., M.Sc., Luis A. Clavell, MD, Peter Cole, MD, Kara A. Kelly, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD, FRCPC, Marshall A. Schorin, MD, Cindy L Schwartz, MD, MPH, Barbara Asselin, MD, Jeffrey G Supko, PhD, Sarah Hunt, MPH, Place Andrew, MD, PhD, Lynda M. Vrooman, MD, Donna S. Neuberg, ScD, Stephen E. Sallan, MD

Blood (2013) 122 (21): 838.

https://doi.org/10.1182/blood.V122.21.838.838

Published: 2013

Journal Articles

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Noopur Raje, MD, Dan T. Vogl, MD, MSCE, Parameswaran N. Hari, MD, MRCP, MS, Sundar Jagannath, MD, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, M.D., Ph.D., Paul G. Richardson, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 759.

https://doi.org/10.1182/blood.V122.21.759.759

Published: 2013

Journal Articles

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group

Wanda L. Salzer, Barbara Asselin, Jeffrey G. Supko, Meenakshi Devidas, Nicole A. Kaiser, Paul Plourde, Naomi J. Winick, Gregory H. Reaman, Elizabeth Raetz, William L. Carroll, Stephen P. Hunger

Blood (2013) 122 (4): 507–514.

https://doi.org/10.1182/blood-2013-01-480822

Published: 2013

Journal Articles

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Noopur Raje, MD, Parameswaran N Hari, MD, MRCP, MS, Dan T. Vogl, MD, MSCE, Sundar Jagannath, MD, Robert Z. Orlowski, M.D., Ph.D., Jeffrey G Supko, PhD, Patricia Stephenson, ScD, Simon S Jones, Catherine Wheeler, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 4061.

https://doi.org/10.1182/blood.V120.21.4061.4061

Published: 2012

Journal Articles

Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01

Lewis B. Silverman, MD, Kristen Stevenson, Lynda M Vrooman, MD, Jeffrey G Supko, PhD, Barbara Asselin, MD, Uma Athale, MD, Luis A. Clavell, MD, Peter Cole, MD, Kara M Kelly, MD, Caroline Laverdiere, MD, Bruno Michon, MD, FRCPC, Marshall A. Schorin, MD, Cindy Schwartz, MD, MPH, Donna Neuberg, ScD, Stephen E. Sallan, MD

Blood (2011) 118 (21): 874.

https://doi.org/10.1182/blood.V118.21.874.874

Published: 2011

Journal Articles

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia

Lewis B. Silverman, Jeffrey G. Supko, Kristen E. Stevenson, Christina Woodward, Lynda M. Vrooman, Donna S. Neuberg, Barbara L. Asselin, Uma H. Athale, Luis Clavell, Peter D. Cole, Kara M. Kelly, Caroline Laverdière, Bruno Michon, Marshall Schorin, Cindy L. Schwartz, Jane E. O'Brien, Harvey J. Cohen, Stephen E. Sallan

Blood (2010) 115 (7): 1351–1353.

https://doi.org/10.1182/blood-2009-09-245951

Published: 2010

Journal Articles

Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: Results From DFCI-ALL Consortium Protocol 00-01.

Lynda M. Vrooman, MD, Donna S. Neuberg, ScD, Kristen E. Stevenson, MS, Jeffrey G. Supko, PhD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2009) 114 (22): 321.

https://doi.org/10.1182/blood.V114.22.321.321

Published: 2009

NARROW

Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium

PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial

Results Of The DFCI ALL Consortium Protocol 05-001 For Children and Adolescents With Newly Diagnosed ALL

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia

Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: Results From DFCI-ALL Consortium Protocol 00-01.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only